ZyVersa data adds evidence of NLRP3 focus in obesity, says Piper Sandler

Piper Sandler analyst Yasmeen Rahimi notes that a publication last week from privately-held NodThera highlighted the potential for NLRP3 in obesity and points out that the firm found data from a case-control study conducted by ZyVersa Therapeutics (VZSA) that showed LP-OBIR-plus increased NLRP and plasma levels of NLRP3 relative to lean individuals, which it says “adds another piece of supporting evidence to validate and implicate NLRP3 biology for obesity.” The firm points out that Ventyx Biosciences’ (VTYX) VTX3232 is currently in Phase 1 study with data guided for Q1 and believes this reporting will be “a key stock moving event,” as it keeps an Overweight rating and $21 price target on Ventyx shares.